Vimta Labs Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹99Cr
- +10% YoY
- −2.9% QoQ
- Net profit
- ₹18Cr
- −18.2% YoY
- −10% QoQ
- Margin
- 35%
- −2 pp YoY
- +1 pp QoQ
Guidance rank: #18 of 34 in Healthcare Services
See the sector's top 10 — free with your mobile number.
The short version
Vimta Labs is confident about good near-term and long-term growth due to favorable markets in pharma, food testing, preclinical and clinical research, and electronics testing. Vimta Labs expresses confidence in continued growth driven by favorable market conditions across pharma, food testing, and electronics sectors. - The company targets INR 500 crores revenue for the next fiscal year but refrains from providing firm forward-looking guidance. - EBITDA margins expected to maintain near current levels (±1-2%) with ongoing digital transformation and AI integration supporting efficiency gains. - Operational challenges caused minor revenue deferrals in Q3, with Q4 projected to show improved performance. - New biologics contract research and development services to commercialize from Q1 FY '27; revenues expected to start small initially. - Firm focus on expanding laboratory capacities and new testing chambers to support growth. - ROCE expected to normalize back above 20% following current investment phase. - Export revenues growing, with approx.
From Vimta Labs Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Vimta Labs is confident about good near-term and long-term growth due to favorable markets in pharma, food testing, preclinical and clinical research, and electronics testing.
- The target of INR 500 crores revenue for the next fiscal year remains aligned.
- Q4 is expected to witness higher revenues, supporting growth trajectory.
- Capacity expansions, including doubling electronics and electrical testing capacity, aim to support sales growth.
- New service lines like biologics contract research and development services are expected to commercialize from Q1 FY ‘27, contributing to future revenue.
- Increasing marketing efforts overseas and adding laboratory facilities will further enable growth.
2 more points from Vimta Labs Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Vimta Labs Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Vimta Labs is continuing to invest in capacity expansion, especially to support growth in defense-related EMI/EMC testing, adding a qualified new chamber recently.
- To sustain growth, the company plans to open more laboratories in the future.
- Recent capex has included significant infrastructure expansion and new biologics, formulation, and process development services.
- Equipment procurement and facility setup for biologics contract research and development services are on track, with commercialization expected by Q1 FY '27.
- Capex typically aligns with depreciation from the previous year to avoid technological obsolescence and support revenue growth.
2 more points from Vimta Labs Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Vimta Labs Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The company has initiated new projects, with one already underway and another in the initiation phase, but their current revenue impact is minimal as the projects are recent.
- Clinical trial bookings experienced some lag in the quarter, leading to deferred revenues.
- Biologics contract research and development services are gearing up, with commercialization expected by Q1 FY '27, though no significant revenues are anticipated immediately.
- Market conditions across pharma, food testing, and electronics testing remain favorable, supporting order book growth.
2 more points from Vimta Labs Ltd's call on order book
Create a free account to keep reading this call
Vimta Labs Ltd — Quarterly revenue & net profit
Vimta Labs Ltd Q3 FY26 results — key figures
| ₹ Cr | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 99 | 90 | +10% | 102 | -2.9% |
| Operating profit (EBITDA) | 34 | 33 | +3% | 34 | 0% |
| Operating margin | 35% | 37% | -2 pp | 34% | +1 pp |
| Profit before tax | 23 | 28 | -17.9% | 26 | -11.5% |
| Net profit (PAT) | 18 | 22 | -18.2% | 20 | -10% |
| EPS (₹) | 3.94 | 4.84 | -18.6% | 4.47 | -11.9% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹112 Cr, net profit ₹21 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Vimta Labs's management said in earlier quarters
Others in Healthcare Services this season
- Vijaya Diagnostic Centre (Q3 FY26)
FY '27 capex of INR 100-120 crores planned, supporting network expansion (Page 5). Key concall takeaways from Vijaya Diagnostic Centre's Q3 FY26 earnings call —
- Aster DM Quality (Q3 FY26)
Mature hospitals show steady revenue growth of 14%, hospitals 3-7 years old growing at 10%, and new assets under 3 years growing at 19%. Key concall takeaways…
- Chandan Healthca (Q3 FY26)
The company plans to open 100 new labs within three years, with an overall capex of INR100 crores for this expansion. Key concall takeaways from Chandan…
- Rainbow Childrens Medicare (Q3 FY26)
Revenue growth for the quarter was 12% YoY; 9% for the first 9 months of the financial year. Key concall takeaways from Rainbow Childrens Medicare Ltd's Q3…
Potential multibaggers · Q2 FY27
Potential multibaggers in Healthcare Services
on management's own guidance
- Strong growth2
- Strong growth1
- IndegeneGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Vimta Labs Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Vimta Labs Ltd Q3 FY26 results?
Vimta Labs is confident about good near-term and long-term growth due to favorable markets in pharma, food testing, preclinical and clinical research, and electronics testing. Vimta Labs expresses confidence in continued growth driven by favorable market conditions across pharma, food testing, and electronics sectors. - The company targets INR 500 crores revenue for the next fiscal year but refrains from providing firm forward-looking guidance. - EBITDA margins expected to maintain near current levels (±1-2%) with ongoing digital transformation and AI integration supporting efficiency gains. - Operational challenges caused minor revenue deferrals in Q3, with Q4 projected to show improved performance. - New biologics contract research and development services to commercialize from Q1 FY '27; revenues expected to start small initially. - Firm focus on expanding laboratory capacities and new testing chambers to support growth. - ROCE expected to normalize back above 20% following current investment phase. - Export revenues growing, with approx.
What is Vimta Labs Ltd share price analysis?
Vimta Labs Ltd currently shows a neutral. The stock trades at a P/E of 34.1 with a market cap of ₹2,757 Cr. Investors should review the full earnings analysis for detailed insights.
Is Vimta Labs Ltd planning capital expenditure?
Vimta Labs is continuing to invest in capacity expansion, especially to support growth in defense-related EMI/EMC testing, adding a qualified new chamber recently.
Keep Vimta Labs Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
